| P2093 | author name string | Norma P Tavakoli | |
| | Michele Caggana | |
| | Melissa Pearce | |
| | Rebecca McMahon | |
| | Breanne Maloney | |
| | Emily C McGrath | |
| | Adam Gearhart | |
| | Amanda Occhionero | |
| | Daniele-Marisa Stansfield | |
| | Lenore DeMartino | |
| | Rhonda Hamel | |
| P2860 | cites work | Neonatal screening for congenital adrenal hyperplasia: experience and results in Argentina | Q46650367 |
| | Newborn screening for congenital adrenal hyperplasia has reduced sensitivity in girls | Q46754970 |
| | Pituitary-adrenal response in preterm very low birth weight infants after treatment with antenatal corticosteroids | Q47300240 |
| | Improved precision of newborn screening for congenital adrenal hyperplasia using weight-adjusted criteria for 17-hydroxyprogesterone levels | Q47319081 |
| | Effect of gender, birth weight and gestational age on serum 17-hydroxyprogesterone concentration and distribution among neonates in Saudi Arabia | Q47347347 |
| | Benefits of neonatal screening for congenital adrenal hyperplasia (21-hydroxylase deficiency) in Sweden. | Q50899622 |
| | Newborn screening for congenital adrenal hyperplasia in New Zealand, 1994-2013. | Q51069880 |
| | [Do we need congenital adrenal hyperplasia screening for premature infants?]. | Q54409256 |
| | Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia. | Q55067438 |
| | Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: Newborn screening and its relationship to the diagnosis and treatment of the disorder | Q57632303 |
| | Worldwide experience in newborn screening for classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency | Q68093490 |
| | Neonatal screening for congenital adrenal hyperplasia: transitory elevation of 17-hydroxyprogesterone | Q84292002 |
| | Neonatal screening for congenital adrenal hyperplasia | Q84427406 |
| | Neonatal screening for congenital adrenal hyperplasia | Q84890191 |
| | Comparison of one-tier and two-tier newborn screening metrics for congenital adrenal hyperplasia | Q85199122 |
| | Ten-year evaluation of a Neonatal Screening Program for congenital adrenal hyperplasia | Q85913322 |
| | Congenital adrenal hyperplasia and the second newborn screen | Q86132619 |
| | Newborn screening for congenital adrenal hyperplasia in Cuba: six years of experience | Q86355290 |
| | Comparison of newborn screening protocols for congenital adrenal hyperplasia in preterm infants | Q87383737 |
| | Nationwide neonatal screening for congenital adrenal hyperplasia in sweden: a 26-year longitudinal prospective population-based study | Q87683353 |
| | Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline | Q24614223 |
| | Genotype-phenotype correlation in 1,507 families with congenital adrenal hyperplasia owing to 21-hydroxylase deficiency | Q24619813 |
| | Global Disorders of Sex Development Update since 2006: Perceptions, Approach and Care | Q28078826 |
| | Characterization of frequent deletions causing steroid 21-hydroxylase deficiency | Q33582394 |
| | Nonclassic Congenital Adrenal Hyperplasia | Q34021657 |
| | A comparative cost analysis of newborn screening for classic congenital adrenal hyperplasia in Texas | Q34200560 |
| | Comprehensive Genetic Analysis of 182 Unrelated Families with Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency | Q34571853 |
| | Longitudinal measurements of 17alpha-hydroxyprogesterone in premature infants during the first three months of life | Q35288771 |
| | The next 150 years of congenital adrenal hyperplasia | Q36055119 |
| | Congenital adrenal hyperplasia cases identified by newborn screening in one- and two-screen states | Q36269153 |
| | Clinical and environmental influences on metabolic biomarkers collected for newborn screening. | Q36501266 |
| | Genotyping Steroid 21-Hydroxylase Deficiency: Hormonal Reference Data* | Q36597628 |
| | Results from 28 years of newborn screening for congenital adrenal hyperplasia in sapporo | Q37733057 |
| | Metabolomics of prematurity: analysis of patterns of amino acids, enzymes, and endocrine markers by categories of gestational age. | Q39317447 |
| | Adrenocortical function in the very low birth weight infant: improved testing sensitivity and association with neonatal outcome | Q40990222 |
| | Classic Congenital Adrenal Hyperplasia due to 21-Hydroxylase-Deficiency: 13 Years of Neonatal Screening and Follow-up in Bavaria | Q41657085 |
| | Newborn screening for congenital adrenal hyperplasia in the Netherlands | Q44013102 |
| | High reliability of neonatal screening for congenital adrenal hyperplasia in Switzerland | Q44126971 |
| | Screening for congenital adrenal hyperplasia: adjustment of 17-hydroxyprogesterone cut-off values to both age and birth weight markedly improves the predictive value | Q44690260 |
| | Rapid second-tier molecular genetic analysis for congenital adrenal hyperplasia attributable to steroid 21-hydroxylase deficiency | Q45193728 |
| | Ethnic and gender differences in rates of congenital adrenal hyperplasia in Western Australia over a 21 year period | Q45653572 |
| | Cutoff levels of 17-alpha-hydroxyprogesterone in neonatal screening for congenital adrenal hyperplasia should be based on gestational age rather than on birth weight | Q46410815 |
| | Estimation of the false-negative rate in newborn screening for congenital adrenal hyperplasia | Q46533292 |
| P921 | main subject | congenital adrenal hyperplasia | Q366868 |
| P304 | page(s) | 1-7 | |
| P577 | publication date | 2016-03-12 | |
| P1433 | published in | Molecular Genetics and Metabolism Reports | Q27725363 |
| P1476 | title | Newborn screening for congenital adrenal hyperplasia in New York State | |
| P478 | volume | 7 | |